AZ Closer To Second Enhertu OK After Gastric Cancer Success
Improved Overall Survival Compared With Chemo
The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.
